Overview

Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma

Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
0
Participant gender:
All
Summary
Purpose:To evaluate whether immediate multiparametric MRI evaluate the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer(MIBC). Rationale:Multiparametric MRI may help detect the early changes of bladder cancer receiving neoadjuvant chemotherapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Criteria
Inclusion Criteria:

- Pathologically confirmed primary or recurrent bladder cancer.

- Planned to undergo transurethral resection of bladder tumor (TURBT) or modified GC
regimen neoadjuvant chemotherapy plus radical total cystectomy.

- 18 years old and older.

- Willing to give valid written informed consent.

- No contraindications to the MRI(magnetic resonance imaging) and MRI contrast agent.

Exclusion Criteria:

- Abnormal liver function (1.5 times higher than normal).

- Glomerular filtration rate < 60ml /min·kg.

- Heart failure.

- Acute myocardial infarction.

- Severe heart and lung disease.

- Hypotension and hypoxia.

- Brain metastases, or other known central nervous system metastases.

- A history of severe central nervous system diseases, including unexplained loss of
consciousness or transient ischemic attack.

- Known congenital or acquired immunodeficiency, active hepatitis, active tuberculosis
and other active infections, etc.

- Pregnant or lactating women.

- Patients participating in other drug trials.

- Patients with poor general condition (eg malnutrition, dehydration). Behavioral status
score (ZPS quintile) ≥ 2.

- Patients with previous autoimmune diseases or existing autoimmune diseases. (including
controlled or uncontrolled drugs).

- Patients undergoing organ transplantation (transplantation of liver, kidney, heart,
lung and other organs) or those who require long-term administration of
immunosuppressive agents due to personal conditions.

- Those who are intolerant or allergic to cytotoxic chemotherapeutic drugs.

- Bone marrow transplantation, severe leukopenia.

- Patients with severe infection or trauma.

- Any condition based on the investigation's clinical judgment that the patient is not
suitable for completing this study (such as not meeting the patient's most beneficial
treatment, patient compliance, etc.)